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HIGHLIGHTS
 SARS-CoV-2 directly infects
cardiomyocytes in patients with COVID-19
myocarditis and does not infect cardiac
macrophages, fibroblasts, or endothelial
cells.
 COVID-19 myocarditis is characterized by
a myeloid-rich inflammatory infiltrate.
 SARS-CoV-2 infects cardiomyocytes
through an ACE2 and endosomal cysteine
protease dependent pathway.
 Infection of hPSC-derived cardiomyocytes
and engineered heart tissues show that
cytokine production, sarcomere disas-
sembly, and cell death were a direct
consequence of cardiomyocyte infection.
 SARS-CoV-2 reduces cardiomyocyte
contractility through sarcomere
breakdown and cardiomyocyte cell death.
ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2021.01.002
From the aDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA;
bCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; cDepart-
ment of Biochemistry andMolecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USA; dWashington
University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, Missouri, USA; eDepartment of
Pathology & Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA;
f
Department of
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 6 , N O . 4 , 2 0 2 1
ª 2 0 2 1 T H E A U T HO R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
SUMMARY
There is ongoing debate as to whether cardiac complications of coronavirus disease-2019 (COVID-19) result
from myocardial viral infection or are secondary to systemic inflammation and/or thrombosis. We provide
evidence that cardiomyocytes are infected in patients with COVID-19 myocarditis and are susceptible to severe
acute respiratory syndrome coronavirus 2. We establish an engineered heart tissue model of COVID-19
myocardial pathology, define mechanisms of viral pathogenesis, and demonstrate that cardiomyocyte severe
acute respiratory syndrome coronavirus 2 infection results in contractile deficits, cytokine production, sarco-
mere disassembly, and cell death. These findings implicate direct infection of cardiomyocytes in the patho-
genesis of COVID-19 myocardial pathology and provides a model system to study this emerging disease.
(J Am Coll Cardiol Basic Trans Science 2021;6:331–45) © 2021 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S evere acute respiratory syndrome-coronavirus-2(SARS-CoV-2) is the cause of the ongoing corona-virus disease-2019 (COVID-19) pandemic. Epide-
miological studies have identified pre-existing
cardiovascular disease as a risk factor for the develop-
ment of severe COVID-19 and mortality [reviewed in
Madjid et al. (1)]. Cardiovascular manifestations of
COVID-19 include elevated troponin, reduced left ven-
tricular (LV) systolic function, and arrhythmias. Cardiac
complications occur in 20% to 44% of hospitalized pa-
tients, and constitute an independent risk factor for
COVID-19 mortality (1–4). Cardiac magnetic resonance
imaging studies have suggested that persistent myocar-
dial injury may be more common than appreciated and
occurs in less severe forms of COVID-19 (5–7). The mech-
anistic basis by which SARS-CoV-2 results in cardiac
dysfunction remains obscure and it is unclear whether
these effects are a result of myocardial infection or a sys-
temic inflammatory response to extracardiac infection
(8).
Investigation of the cardiac manifestations of
COVID-19 has remained challenging. Rigorous ana-
lyses of cardiac tissue obtained from affected patients
are lacking. Furthermore, there are few animal
models to study cardiovascular complications
observed in SARS-CoV-2–infected humans (9). The
most commonly used laboratory animal model, the
mouse, is not susceptible to SARS-CoV-2 infection
due to poor affinity of the viral spike protein for
murine angiotensin converting enzyme 2 (ACE2).
Transgenic mice that express human ACE2 under the
control of the cytokeratin 18 promotor do not reca-
pitulate ACE2 expression within the human cardio-
vascular system (10–12). Therefore, there is a critical
need to develop robust model systems that enable the
investigation of the cardiovascular complications of
COVID-19.
We used human myocardial specimens and
devised an engineered heart tissue (EHT) model of
COVID-19 myocarditis to test the hypothesis that
SARS-CoV-2 promotes cardiac pathology by infecting
cardiomyocytes and activating local immune re-
sponses. EHT provide unique advantages as model
systems for studying COVID-19 cardiac pathology
because they generate contractile force, display
electrical coupling, promote maturation of human
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FIGURE 1 Specimens From Patients With Severe COVID-19 Myocarditis Show Evidence of SARS-CoV-2 Cardiomyocyte Infection
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pluripotent stem cell (hPSC)–derived cardiomyocytes,
and have cellular organization that mimics myocar-
dial tissue (12–14). These studies show that car-
diomyocytes are a target of SARS-CoV-2, link
cardiomyocyte infection to disease pathogenesis, and
establish EHT as an experimentally tractable model of
COVID-19 myocardial pathology.
METHODS
A detailed methods section, including Supplemental
Tables 1 and 2, is in the Supplemental Appendix.
BIOSAFETY. This study was approved by the IRB of
Washington University Medical School. All work with
infectious SARS-CoV-2 was performed in a biosafety
level 3 facility by personnel equipped with a powered
air purifying respirator.
VIRUSES. The 2019n-CoV/USA_WA1/2019 isolate of
SARS-CoV-2 was obtained from the United States
Centers for Disease Control. Information on the
NeonGreen SARS-CoV-2-NeonGreen virus was dis-
cussed in Xie et al. (13). All infections were performed
at a multiplicity of infection (MOI) of 0.1.
hPSC CARDIOMYOCYTE DIFFERENTIATION AND
EHTs. Stem cells were differentiated by temporal
manipulation of Wnt signaling and metabolic se-
lection. EHTs were assembled in poly-
dimethylsiloxane (PDMS) casting molds (EHT
Technologies, Hamburg, Germany) from hPSC-
derived cardiomyocytes, fibroblasts, and/or macro-
phages. EHTs were inoculated with SARS-CoV-2 at
least 7 days after tissue seeding.
STATISTICAL ANALYSIS. Statistical tests were cho-
sen based on accepted standards. The Kolmogorov-
Smirnov test was used to test for normality. Para-
metric (Student t test, analysis of variance
[ANOVA]) and nonparametric (Mann-Whitney test)
statistical methods were used when appropriate.
Statistical significance was assigned when p values
were <0.05 using Prism Version 8 (GraphPad, San
Diego, California). Specific tests are indicated in the
figure legends. Mean values and median values are
displayed for parametric tests and nonparametric
tests, respectively.
RESULTS
EVIDENCE OF CARDIOMYOCYTE INFECTION IN SEVERE
COVID-19 MYOCARDITIS. The pathology of COVID-19
myocarditis remains poorly understood. We ob-
tained autopsy and endomyocardial biopsy speci-
mens from 4 subjects with SARS-CoV-2 infection and
clinical diagnoses of myocarditis. Myocardial injury
and LV systolic dysfunction were present in each case
(Supplemental Table 3). Coronary angiography
showed no evidence of luminal stenosis or throm-
bosis. The presence of SARS-CoV-2 RNA from naso-
pharyngeal samples was confirmed by clinical
polymerase chain reaction (PCR) testing.
Postmortem microscopic examination of the LV
myocardium showed areas of cardiomyocyte necrosis
and degenerative vacuolization of cardiomyocyte
cytoplasm accompanied by a mononuclear cell infil-
trate (Figure 1A). These changes were distinct from
postmortem autolytic changes. Examination of the
coronary arteries from COVID-19 myocarditis autopsy
cases showed nonobstructive mild atherosclerotic
changes, consistent with angiogram findings. There
was no evidence of microvascular injury or throm-
boembolic events. Autopsy heart samples from sub-
jects with metastatic carcinoma and an inherited
neurodegenerative disease with similar tissue pro-
curement times were included as negative controls.
SARS-CoV-2 spike and nucleocapsid RNA was
detected within the myocardium of each COVID-19
myocarditis subject. Viral transcripts were located in
cytoplasmic and perinuclear locations within cells
that were morphologically consistent with car-
diomyocytes (Figure 1B). Viral transcripts were also
present lung airway epithelial cells and rare myocar-
dial adipocytes and pericytes (Supplemental
Figure 1). Immunostaining for the SARS-CoV-2
nucleocapsid protein showed presence of viral pro-
tein in cardiomyocytes (Figure 1C). The immune cell
infiltrate was characterized by accumulation of an
FIGURE 1 Continued
(A) Hematoxylin and eosin staining of cardiac autopsy (anterior left ventricular wall) and biopsy samples (right ventricular septum) from subjects without coronavirus
disease-2019 (COVID-19) (control case) and patients with severe COVID-19 myocarditis (case 1-4). (B) In situ hybridization for severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) spike and nucleocapsid RNA (red). Hematoxylin: blue. The arrows denote viral RNA staining in cells with cardiomyocyte morphology. (C)
Immunostaining of control and COVID-19 myocarditis cardiac autopsy tissue for SARS-CoV-2 nucleocapsid (white) and cardiac actin (red). DAPI: blue. The arrows
denote nucleocapsid staining in cardiomyocytes. (D) Immunostaining of control and COVID-19 myocarditis specimens for CD68 (green) and CCR2 (red). DAPI: blue.
(E) Immunostaining of control and COVID-19 myocarditis tissue for CD3 (brown). Hematoxylin: blue. DAPI ¼ 40,6-diamidino-2-phenylindole.
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FIGURE 2 SARS-CoV-2 Infects Cardiomyocytes
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admixture of CCR2- and CCR2þ macrophages
(Figure 1D). Minimal T-cell infiltration was noted
(Figure 1E). Macrophage abundance was highest in
areas of cardiomyocyte injury as depicted by com-
plement deposition (C4d staining, Spearman r ¼ 0.86,
p ¼ 0.0005), a pathological marker of cardiomyocyte
cell death (14–16) (Supplemental Figure 1). These ob-
servations suggest that SARS-CoV-2 can infect the
human heart and may contribute to cardiomyocyte
cell death and myocardial inflammation.
SARS-CoV-2 TROPISM IN THE HUMAN HEART. ACE2
serves as a cell-surface receptor for SARS-CoV-2
through interactions with the spike protein (17,18).
Consistent with prior reports, we detected ACE2
mRNA expression in the human heart across the
spectrum of age increasing in heart failure (19,20).
ACE2 mRNA was expressed in cardiomyocytes with
significant variation in ACE2 protein expression be-
tween individual cardiomyocytes. hPSC-derived car-
diomyocytes and EHTs expressed ACE2 mRNA and
protein (Supplemental Figures 2 and 3).
To determine the susceptibility of different
myocardial cell types to SARS-CoV-2 infection, we
inoculated combinations of hPSC-derived car-
diomyocytes, fibroblasts, and macrophages with
wild-type SARS-CoV-2 (USA_WA1/2019). We analyzed
tissue culture supernatants for production of infec-
tious virus and measured intracellular viral RNA
transcript levels at 3 days post-inoculation. These
assays revealed production of infectious virus
(Figure 2A) and viral RNA (Figure 2B) in cultures that
contained hPSC-derived cardiomyocytes. Cultures
lacking hPSC-derived cardiomyocytes contained viral
loads that were equivalent to media-only controls.
To verify cardiomyocyte selective tropism, we
inoculated human cardiac stromal populations with a
recombinant SARS-CoV-2 clone containing a Neon-
Green fluorescent reporter (SARS-CoV-2-NeonGreen)
(13). NeonGreen is expressed from a viral subgenomic
RNA, indicative of active viral replication. Primary
human cardiac fibroblasts, endothelial cells, and
macrophages were not permissive to SARS-CoV-2
infection (Supplemental Figures 3 to 5). hPSC-
derived endothelial cells and cardiac fibroblasts
were also not susceptible to infection. In contrast, 2
independent lines of hPSC-derived cardiomyocytes
were permissive to SARS-CoV-2 infection. Undiffer-
entiated hPSC lines did not show evidence of infec-
tion (Supplemental Figure 5). hPSC-derived
cardiomyocyte infection showed rapid production of
infectious virus with peak titers on day 3 post-
inoculation (Figure 2C).
We examined the relationship between viral
replication and cell death. NeonGreen-positive car-
diomyocytes peaked at day 3 post-inoculation. hPSC-
derived cardiomyocyte cell death was observed
beginning 4 to 5 days post-inoculation (Figure 2D)
indicating that viral infection precedes cell death.
SARS-CoV-2–infected cardiomyocytes displayed
characteristics of cytopathic effect, cellular rounding,
clumping, and syncytium formation. Distortion of
cellular morphology was evident by day 4 post-
inoculation and cultures contained largely dead
cells and debris by days 5 to 6 post-inoculation
(Figure 2E).
To examine whether cardiomyocytes are a target of
SARS-CoV-2 in a simulated cardiac environment, we
infected 2-dimensional tissues assembled with hPSC-
derived cardiomyocytes (80%), fibroblasts (10%), and
macrophages (10%) with SARS-CoV-2-NeonGreen.
Flow cytometry performed 3 days following infection
revealed NeonGreen expression only in
FIGURE 2 Continued
(A) Focus-forming assay measuring production of infectious virus from human pluripotent stem cell (hPSC)–derived cardiomyocytes (CM), fibroblasts (Fb), and
macrophages (Mac) inoculated with SARS-CoV-2 (multiplicity of infection [MOI], 0.1). Media only denotes wells that contain no cells. Assays were performed 3 days
following inoculation. Dashed line indicates limit of assay detection. (B) Quantitative real-time polymerase chain reaction (RT-PCR) showing viral N-gene copies in
cultures containing CM, Fb, and Macs inoculated with SARS-CoV-2 (MOI 0.1). RNA was collected 3 days post-inoculation (n ¼ 5 per group). (C) Focus-forming assay
measuring infectious SARS-CoV-2 (black line indicates wild-type; green line indicates NeonGreen) in supernatant of hPSC-derived cardiomyocytes over time
following inoculation (MOI 0.1). A dashed line indicates the limit of detection (n ¼ 4 per group). (D) Two-dimensional cultures of hPSC-derived cardiomyocytes were
inoculated with SARS-CoV-2 (MOI 0.1) and analyzed for viability (Zombie-Violet) and infection (NeonGreen) as a function of time by flow cytometry. Right plot shows
viability of NeonGreen-positive cells (n ¼ 4 per group). (A–D) Mean values are plotted and error bars denote standard error of the mean. (E) Brightfield microscopy
showing cytopathic effect in hPSC-derived cardiomyocytes infected with SARS-CoV-2 (MOI 0.1). Representative images from 5 individual samples. (F) Flow cytometry
of 2-dimensional tissues containing CM and Fb (left) or CM, Fb, and Mac (right) harvested on day 3 following mock infection or inoculation with SARS-CoV-2 (MOI 0.1).
Representative plot from 4 independent samples. Cardiomyocytes (CD90-CD14-) showed prominent NeonGreen fluorescence (green overlay). NeonGreen signal was
not detected in fibroblasts (CD90þCD14-) or macrophages (CD90-CD14þ). (G) Quantification of NeonGreen-positive cells from 2-dimensional tissues containing
hPSC-cardiomyocytes and fibroblasts or hPSC-cardiomyocytes, fibroblasts, and macrophages (n ¼ 4 per group). Bars denotes median value. *p < 0.05 compared to
mock infection (Mann-Whitney test). (H) Transmission electron microscopy micrographs of cardiomyocytes in 2-dimensional tissues infected with either mock or SARS-
CoV-2 (MOI 0.1). Tissues were harvested on day 3 post-inoculation. Viral budding (blue arrow) and endosomal compartments filled with virions (black arrow) are
denoted. Scale bars in insets are 100 nm. Representative image from 4 independent samples. FFU ¼ focus forming units; other abbreviation as in Figure 1.
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FIGURE 3 RNA Sequencing Identified Viral Transcription and Activation of Innate Immune Response in hPSC-Derived Cardiomyocytes and Tissues
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CD90-CD14-TNNT2þ cardiomyocytes. NeonGreen was
not detected in CD90þ fibroblasts or CD14þ macro-
phages (Figures 2F, 2G and Supplemental Figure 6).
Transmission electron microscopy of 2-dimensional
tissues performed 3 days post-inoculation showed
the presence of coronavirus particles within infected
hPSC-derived cardiomyocytes. Micrographs revealed
structural features of coronaviruses including the
presence of a trilaminar envelope and characteristic
cross-sections through the nucleocapsid (Figure 2H)
(21,22). Virions were identified within perinuclear
endosomal-like structures of hPSC-derived car-
diomyocytes. We observed various stages of virion
assembly including budding from intracellular mem-
branes. Virions were not detected in mock-infected
cardiomyocytes.
RNA SEQUENCING IDENTIFIED ROBUST VIRAL
TRANSCRIPTION AND ACTIVATION OF INNATE
IMMUNE RESPONSES. To examine viral transcription
and the host immune response to SARS-CoV-2 infec-
tion, we performed RNA sequencing. Cultures con-
taining either hPSC-derived cardiomyocytes,
fibroblasts, or macrophages were either mock-
infected or inoculated with SARS-CoV-2. We also
examined 2-dimensional tissues assembled with 80%
cardiomyocytes, 10% fibroblasts, and 10% macro-
phages. Cells and tissues were harvested on day 3
post-inoculation. Multidimensionality reduction
analysis revealed separation between experimental
groups consistent with their distinct cellular compo-
sition (Figure 3A). Infected hPSC-derived car-
diomyocytes and 2-dimensional tissues contained
abundant viral genomic and subgenomic RNAs iden-
tified based on the presence of 5’ leader sequences
(Figure 3B and Supplemental Figure 7) (23).
Numerous host genes were differentially regulated
upon SARS-CoV-2 infection in each of the examined
cell types and 2-dimensional tissues (Figure 3C).
Conditions that supported viral replication (hPSC-
derived cardiomyocytes and 2-dimensional tissues)
displayed the greatest overlap in differentially
expressed genes. Cell types that did not support viral
replication (fibroblasts and macrophages) also
showed differentially expressed host genes
(Figure 3D), suggesting that SARS-CoV-2 virions
stimulate host gene expression in the absence of
direct viral infection. Pathway analysis revealed that
infected hPSC-derived cardiomyocytes and 2-
dimensional co-culture tissues showed upregulation
of genes associated with immune cell activation,
stress-induced transcription, and responses to viral
pathogens. Genes associated with muscle contrac-
tion, metabolism, oxidative phosphorylation, and
mitochondrial function were downregulated
(Figures 3E and 3F). Host genes differentially
expressed in macrophages and fibroblasts were
associated with pathways involved in innate immune
cell activation, migration, and cytokine responses
(Figures 3G and 3H).
Specific genes downregulated in infected hPSC-
derived cardiomyocytes and 2-dimensional tissues
(Figure 3I) included components of the electron
transport chain (adenosine triphosphate synthase,
mitochondrial cytochrome C oxidase, and nicotin-
amide adenine dinucleotide phosphate dehydroge-
nase) and metabolic enzymes (glycerol-3-phosphate
dehydrogenase, pyruvate dehydrogenase, and succi-
nate dehydrogenase complex). PDK4, an inhibitor of
pyruvate dehydrogenase, was upregulated in infected
hPSC-derived cardiomyocytes and 2-dimensional tis-
sues. Components of the contractile apparatus
including cardiac actin, troponins, myosin light and
heavy chains, desmin, phospholamban, and calse-
questrin were downregulated in infected 2-
dimensional tissues. ACE2 expression was dimin-
ished in infected cardiomyocytes and 2-dimensional
tissues. Infected hPSC-derived cardiomyocytes and
2-dimensional tissues displayed upregulation of
innate immune mediators including IFNB1 and
interferon (IFN)– stimulated genes (IFIT1, IFIT2,
IFIT3, ISG15, MX1, and OAS1), early response genes
FIGURE 3 Continued
(A) MDS plot of RNA sequencing data obtained from mock and SARS-CoV-2–infected (MOI 0.1) hPSC-derived CMs, Fbs, Macs, and 2-dimensional tissues (CM þ Fb þ
Mac). Cells and tissues were harvested on day 3 post-inoculation (n ¼ 5 per group). (B) Heatmap of SARS-CoV-2 viral gene expression. Color scale denotes absolute
expression as log2 counts per million reads (CPM) (scale: blue ¼ 0, red ¼ 15). (C) Volcano plots showing differentially expressed genes between mock and SARS-CoV-2–
infected conditions. Black dots indicate no significant change, red dots indicate upregulated during infection (log2 fold change>2, FDR p < 0.05), and blue dots
indicate downregulated during infection (log2 fold change<2, FDR p < 0.05). Data points correspond to individual transcripts. (D) Venn diagram of genes upre-
gulated and downregulated in each cell type and tissues. Differential expression is based on change relative to corresponding uninfected (mock) samples. (E to H) Gene
ontology (GO) pathway analysis of CM (E), CM þ Fb þ Mac (F), Mac (G) and Fib (H) showing top 5 upregulated (red) and downregulated (blue) pathways in SARS-CoV-
2–infected samples compared to mock. Color indicates log2 fold change (log2FC). (I) Heat maps of selected differentially expressed genes implicated in metabolism
(left), contractile apparatus (center), and immune response (right). CM and tissues (CM þMac þ Fb) are displayed. Color scale denotes relative gene expression (high
red, low blue) across cell types and conditions. ATP ¼ adenosine triphosphate; FDR ¼ false discovery rate; IL ¼ interleukin. other abbreviations as in Figures 1 and 2.
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FIGURE 4 EHTs Recapitulate Aspects of COVID-19 Myocarditis
(A) Hematoxylin and eosin (H&E)–stained sections of 3-dimensional engineered heart tissue (EHT) consisting of hPSC-derived CM, Fbs, and
Macs 5 days following mock infection or inoculation with SARS-CoV-2 (MOI 0.1). Insets are high-magnification images of the boxed areas.
Representative images from 4 independent samples. (B) Immunostaining of mock or SARS-CoV-2–infected 3-dimensional EHTs for sarcomeric
actin (cardiomyocytes, red), CD68 (macrophages, green), and nucleocapsid protein (white). EHTs were harvested 5 days post-inoculation.
Blue: DAPI. Representative images from 4 independent samples. (C) Quantitative RT-PCR of SARS-CoV-2 N-gene expression in EHTs
consisting of hPSC-derived CM, Fb, and/or Macs. EHTs were either mock infected or inoculated with SARS-CoV-2 (MOI 0.1) and harvested
5 days post-inoculation. Error bars denote SE of the mean. Dotted line: limit of detection. *p < 0.05 compared to uninfected control (mock,
Student t test test). (D) In situ hybridization for SARS-CoV-2 spike RNA sense and antisense strands (red) in EHTs 5 days after mock or SARS-
CoV-2 infection (MOI 0.1). Blue: hematoxylin. Representative images from 4 independent specimens. Insets are high magnification images
of the boxed areas. (E) Spontaneous beating displacement traces for infected and uninfected EHTs on day 5 post-infection. (F) Displacement
(relative to uninfected mock condition) generated by spontaneous beating of EHTs as a function of time following inoculation with SARS-CoV-
2 (MOI 0.1). Each data point represents a mean value from 4 to 7 independent samples, error bars denote SE of the mean. (G) Quantification
of absolute displacement (left) and contraction speed (right) generated by spontaneous beating of EHTs 5 days following mock or SARS-
CoV-2 infection (MOI 0.1). Error bars represent SE of the mean; *p < 0.05 compared to mock (Student’s t-test test). Abbreviations as in
Figures 1 and 2.
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FIGURE 5 Mechanisms of Reduced EHT Contractility
Continued on the next page
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(FOS), and cytokines (TNF). Consistent with a greater
innate immune response in 2-dimensional tissues,
several chemokines (CCL3, CCL4, CCL7, CCL8, and
CXCL8) and cytokines (IL1B, IL6, and CSF3) were
selectively upregulated in infected 2-dimensional
tissues. Macrophages and fibroblasts contributed to
enhanced chemokine and cytokine expression in 2-
dimensional tissues. CCL3, CCL4, and CCL8 were
selectively expressed in infected macrophages and
CSF3, CXCL8, IL1B, and IL6 were induced in infected
fibroblasts (Supplemental Figure 7).
SARS-CoV-2 ENTRY INTO CARDIOMYOCYTES IS
MEDIATED BY ACE2 AND ENDOSOMAL CYSTEINE
PROTEASES. A neutralizing human ACE2 (viral re-
ceptor) antibody abrogated SARS-CoV-2–NeonGreen
infectivity as measured by NeonGreen-positivity and
viral RNA extracted from the supernatant of infected
cultures. The extent of blockade was comparable to
treatment with remdesivir, a potent inhibitor of the
SARS-CoV-2 RNA-dependent RNA polymerase (24–26)
(Supplemental Figure 8). After binding to ACE2, the
spike protein must undergo proteolytic activation to
initiate membrane fusion (27). Host proteases located
at the plasma membrane (TMPRSS2) or within endo-
somes (cathepsins) most commonly perform this
function. The relative contributions of each of these
protease families to SARS-CoV-2 infection varies by
cell type (17,27). hPSC-derived cardiomyocytes ex-
press multiple endosomal proteases including ca-
thepsins and calpains. Low levels of transmembrane
protease, serene 2 (TMPRSS2) mRNA were detected in
hPSC-derived cardiomyocytes, but not in fibroblasts
or macrophages (Supplemental Figure 8). To deter-
mine whether SARS-CoV-2 enters cardiomyocytes
through an endosomal or plasma membrane route, we
inoculated hPSC-derived cardiomyocytes with SARS-
CoV-2–NeonGreen and administered either the
endosomal cysteine protease inhibitor E-64, which
blocks cathepsins, or the serine protease inhibitor
camostat mesylate, which blocks TMPRSS2 (and
possibly TMPRSS4) (27). E-64 abolished SARS-CoV-2
infection of hPSC-derived cardiomyocytes as shown
by reduced NeonGreen expression and viral RNA
within the supernatant. Camostat had no effect on
cardiomyocyte infection over a range of doses that
significantly affect SARS-CoV-2 infection of lung-
derived cell lines where TMPRSS2 mediates viral en-
try (17). Laboratory cultivated SARS-CoV-2 stocks
have acquired a mutation in the furin cleavage site,
which alters the preference for proteases (TMPRSS2
vs. cathepsins) that mediate SARS-CoV-2 entry
(27–29). To assess the impact this mutation on car-
diomyocyte infectivity and entry, we inoculated
hPSC-derived cardiomyocytes with either wild-type
SARS-CoV-2 or recombinant SARS-CoV-2 containing
the furin cleavage site mutation (DPRRA). Both vi-
ruses readily infected cardiomyocytes through an
endosomal-dependent mechanism (Supplemental
Figure 8).
EHT MODEL COVID-19 MYOCARDITIS. To examine
whether SARS-CoV-2 infection of EHTs mimics as-
pects of COVID-19 myocarditis, we generated EHTs
containing hPSC-derived cardiomyocytes, fibroblasts,
and macrophages. EHTs were seeded in a collagen-
FIGURE 5 Continued
(A) Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) stain (red) and cardiac actin (green) immunostaining of EHTs (CM þFb þ Mac) 5 days after
mock or SARS-CoV-2 infection (MOI 0.1). Blue: DAPI. Representative images from 4 independent experiments. (B) Quantification of TUNEL-positive cells in areas of
viral infection. Error bars represent SE of the mean, *p < 0.05 compared to mock (Student t test). (C) Immunostaining of hPSC-derived cardiomyocytes for troponin T
(red) 3 days after inoculation with mock control or SARS-CoV-2–NeonGreen (MOI 0.1). Blue: DAPI. Arrows denote areas of sarcomere disassembly. (D) Immunostaining
of EHTs for troponin T (red) and SARS-CoV-2 nucleocapsid (green) 5 days after inoculation with mock control or SARS-CoV-2–NeonGreen (MOI 0.1). Blue: DAPI.
Arrows denote SARS-CoV-2 nucleocapsid–positive cells with reduced troponin T staining. (E) Quantification of troponin T staining in mock (white) and SARS-CoV-2
infected (red) EHTs. Data is presented as mean florescence intensity (MFI). MFI was measured in infected (nucleocapsid-positive [NPþ]) cardiomyocytes and uninfected
(NP-) cardiomyocytes located proximal or remote to areas of infection. Error bars represent SE of the mean, *p < 0.05 compared to mock (Student t test). (F)
Quantitative RT-PCR measuring OAS1, MX1, and tumor necrosis factor (TNF) mRNA expression in hPSC-derived cardiomyocytes 3 days post-inoculation with mock
control (white) or SARS-CoV-2 (green, MOI 0.1). Cells were treated with vehicle, angiotensin-converting enzyme 2 antibody (ACE2 Ab) (20 mg/ml), remdesivir (10 mM),
or TBK inhibitor (MRT67307, 10mM). Error bars indicate SE of the mean. *p < 0.05 compared to mock control (Student t test). (G) Quantitative RT-PCR of SARS-CoV-2 N
gene expression in hPSC-derived cardiomyocytes that were either mock infected (white) or inoculated with SARS-CoV-2 (green, MOI 0.1) and harvested 3 days post-
inoculation. Error bars denote SE of the mean. Dotted line: limit of detection. *p < 0.05 compared to uninfected control (analysis of variance [ANOVA]) or vehicle
infected as indicated by the bar (ANOVA). (H,I) Flow cytometry measuring the percent of infected (H) and viable (I) cardiomyocytes following either mock infection
(white) or inoculation with SARS-CoV-2 (green, MOI 0.1). Cells were harvested and analyzed 3 days post-inoculation. Error bars denote SE of the mean. *p < 0.05
compared to uninfected control (ANOVA). (J) Quantitative RT-PCR measuring TNNT2 mRNA expression 3 days post-inoculation with mock control (white) or SARS-
CoV-2 (green, MOI 0.1). Error bars indicate SE of the mean. *p < 0.05 compared to mock control (ANOVA). (K) Immunostaining for troponin T (red) 3 days post-
inoculation with mock control or SARS-CoV-2–NeonGreen (MOI 0.1). Blue: DAPI. Arrows denote areas of sarcomere disassembly. Abbreviations as in Figures 1 and 2.
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Matrigel matrix between 2 PDMS posts, infected with
SARS-CoV-2, and harvested 5 days after inoculation.
Hematoxylin and eosin staining revealed increased
interstitial cell abundance within the periphery of
SARS-CoV-2–infected EHTs (Figure 4A). Immuno-
staining for the viral nucleocapsid protein demon-
strated evidence of infected cardiomyocytes at the
periphery of the tissue, possible representing limited
diffusion of the virus in the EHT environment. CD68
immunostaining showed macrophage accumulation
corresponding to sites of viral infection (Figure 4B,
Supplemental Figure 9). Infected EHTs accumulated
high levels of viral RNA (Figure 4C). In situ hybridi-
zation for viral spike sense and antisense RNA indi-
cated active viral replication within EHTs (Figure 4D)
(Supplemental Figure 10).
As reduced LV systolic function has been reported
in severe cases of COVID-19 myocarditis, we exam-
ined the effect of SARS-CoV-2 infection on EHT
contractility (30). We calculated the average peak
displacement and velocity for each spontaneously
contracting tissue (Videos 1 and 2). EHTs consisting of
hPSC-derived cardiomyocytes and fibroblasts were
inoculated with SARS-CoV-2, and contractile function
analyzed daily. SARS-CoV-2–inoculated tissues
showed reduced contraction, speed of contraction,
and relaxation relative to the mock-infected tissues
(Figures 4E to 4G).
To examine whether cardiomyocyte cell death
might serve as a mechanism explaining reduced
EHT contractility, we performed terminal deoxy-
nucleotidyl transferase dUTP nick end labelling
(TUNEL) staining and observed increased numbers
of TUNEL-positive cardiomyocytes in SARS-CoV-2–
infected EHTs on day 5 post infection (Figures 5A
and 5B). Our RNA sequencing data suggested that
other mechanisms also may contribute to reduced
EHT contractility, including sarcomere structure,
metabolism, and/or host immune responses
(Figure 3I). Immunostaining of hPSC-derived car-
diomyocytes infected with SARS-CoV-2 revealed
evidence of sarcomere loss 3 days following infec-
tion (Figure 5C), a time point that preceded cell
death. Immunostaining of EHTs showed reduced
troponin T expression in infected cardiomyocytes
(Figures 5D and 5E).
We then examined the mechanistic relationship
between cardiomyocyte infection, inflammatory
signaling, sarcomere loss, and cell death. Inhibition of
viral entry (ACE2 neutralizing antibody) or viral
replication (remdesivir) was sufficient to prevent type
I IFN and tumor necrosis factor (TNF) expression
following SARS-CoV-2 infection (Figures 5F and 5G).
Remdesivir similarly reduced inflammatory gene
expression in 3-dimensioinal EHTs (Supplemental
Figure 11), establishing that viral infection repre-
sents the upstream driver of inflammation in our
model system.
To examine the impact of cardiomyocyte inflam-
matory signaling on cell death, sarcomere gene
expression, and sarcomere structure, we focused on
inhibiting viral nucleic acid sensing in 2-dimensional
cultures given their amenability to flow cytometry
and high-resolution imaging. TANK-binding kinase 1
(TBK1) is an essential mediator of nucleic acid
sensing pathways including RIG-I, MAVS, STING, and
TLRs (31,32). Inhibition of TBK1 activity reduced type
I IFN activity (inflammatory signature in infected
cardiomyocytes) (Figure 3I) without impacting viral
load, cardiomyocyte infectivity, or cell death
(Figures 5F to 5I). While TBK1 inhibition prevented
reductions in TNNT2 and MYH7 mRNA expression
following SARS-CoV-2 infection, sarcomere break-
down remained prevalent. In contrast, remdesivir
prevented both reductions in TNNT2 and MYH7
mRNA expression and sarcomere loss following
SARS-CoV-2 infection (Figures 5J, 5K, and
Supplemental Figure 11). These data indicate that
sarcomeric disassembly and cardiomyocyte cell death
are the result of cardiomyocyte infection and not
inflammation in the EHT system.
DISCUSSION
Whether cardiac manifestations of COVID-19 are a
result of viral infection, systemic inflammation,
and/or microvascular thrombosis remains a debated
topic. We examined myocardial specimens obtained
from individuals with severe COVID-19 myocarditis
and revealed evidence of cardiomyocyte infection,
cell death, and macrophage infiltration. These find-
ings are consistent with prior reports highlighting
infiltration of monocytes, lymphocytes, and plasma
cells in an endomyocardial biopsy specimen from a
patient with suspected COVID-19 myocarditis and
viral RNA within the myocardium of COVID-19 au-
topsy specimens (33,34). The specimens examined in
this study differ substantially from published autopsy
series, which did not include subjects with cardiac
manifestations (3,35). Here, we exclusively focused
on subjects with COVID-19 infection and severe
myocarditis based on echocardiography and clinical
presentation.
We further provide evidence that SARS-CoV-2 in-
fects and replicates within human cardiomyocytes.
SARS-CoV-2 was unable to replicate in cardiac
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fibroblasts, endothelial cells, and macrophages. It
remains possible that SARS-CoV-2 could also infect
other cardiac cell types that are difficult to isolate
from the human heart such as pericytes and endo-
cardial cells. Despite these limitations, our findings
clearly show that cardiomyocytes are a target of
SARS-CoV-2 infection.
To gain insights into the mechanistic basis of
cardiomyocyte infection and myocarditis, we
developed a human EHT system that recapitulates
features of SARS-CoV-2–induced myocarditis. We
provide evidence that SARS-CoV-2 infects hPSC-
derived cardiomyocytes, resulting in reduced
metabolic and contractile apparatus gene expres-
sion, sarcomeric disassembly, inflammatory
signaling, and cell death. Viral entry was ACE2-
dependent and relied on endosomal cysteine pro-
tease activity. Our findings are consistent with a
recent report suggesting that SARS-CoV-2 infects
human cardiac slices, hPSC-derived cardiomyocytes
in an ACE2 and cathepsin-dependent manner, and
impacts the beating of cardiospheres (36). We
extend these observations to show that car-
diomyocytes supported viral replication, rapidly
produced infectious virions, activated type I IFN
signaling, and displayed cytopathic features seen
with coronavirus infection. Infected EHTs showed
reduced contractile force, sarcomere disassembly,
and pathological evidence of myocarditis including
macrophage activation.
Extrapulmonary cell types are susceptible to
SARS-CoV-2 infection (37–39). This broader cellular
tropism is dictated by ACE2 expression and the
ability of the virus to gain access to extrapulmo-
nary tissues. Whether SARS-CoV-2 enters the heart
through hematological seeding and/or direct
extension from the pleural cavity remains un-
known. Among myocardial cell types, car-
diomyocytes and pericytes express ACE2 mRNA
(19). Cardiac fibroblasts and vascular smooth mus-
cle cells may also express ACE2 (20). We showed
that ACE2 is preferentially expressed in car-
diomyocytes and is essential for SARS-CoV-2 to
infect cardiomyocytes. It remains to be explored
whether cardiomyocyte maturation or remodeling
impact vulnerability to viral infection. This possi-
bility is supported by the heterogeneous expression
of ACE2 in the human heart and may explain why
pre-existing cardiovascular disease represents a
strong risk factor for COVID-19 mortality. Consis-
tent with this idea, ACE2 expression is increased in
heart failure (30,40).
EHTs provided an opportunity to gain insights into
the relationship between cardiomyocyte infection,
myocardial inflammation, and contractile dysfunc-
tion. Infection of EHTs resulted in inflammatory
mediator generation, decreased ACE2 expression,
cardiomyocyte cell death, sarcomere breakdown, and
reduced sarcomeric and metabolic gene expression.
Each of these mechanisms likely contributes to
diminished EHT contractility. We showed that car-
diomyocyte infection triggers inflammatory gene
expression, sarcomere loss, and cell death. Blockade
of viral nucleic acid sensing pathways did not prevent
sarcomere disassembly or cardiomyocyte cell death.
Despite the limitations of the inherent immaturity of
hPSC-derived cardiomyocytes and incomplete repre-
sentation of human myocardial cell types included in
EHTs, these findings highlight the central role of
cardiomyocyte infection and suggest that targeting
viral cell entry, replication, or sarcomere breakdown
may improve outcomes in patients with cardiac
complications of COVID-19. The relevance of ACE2
downregulation in infected cardiomyocytes will
require further clarification as Ace2-/- mice display LV
systolic dysfunction and heart failure (41).
STUDY LIMITATIONS. While our findings implicate
that SARS-CoV-2 cardiomyocyte infection likely con-
tributes to myocardial dysfunction, our findings do
not exclude an important role for inflammation or
microthrombi in COVID-19 cardiac pathology. Mac-
rophages and fibroblasts likely contribute to the in-
flammatory response. Despite resistance to SARS-
CoV-2 infection, macrophages and fibroblasts gener-
ated inflammatory mediators when exposed to SARS-
CoV-2. This response could be a result of direct
recognition of viral RNAs and proteins or communi-
cation with infected cardiomyocytes through pro-
duction of soluble mediators or intercellular transfer
via gap junctions. Future studies are necessary to
dissect the cellular mechanisms and signaling path-
ways that initiate and convey the adverse impact of
myocardial inflammation.
CONCLUSIONS
This study provides evidence that cardiomyocytes
are a target of SARS-CoV-2 in the human heart and
support the conclusion that SARS-CoV-2 infection of
cardiomyocytes and resultant myocardial injury and
inflammation contribute to the cardiac manifesta-
tions of COVID-19. We show that SARS-CoV-2
infection of 2-dimensional cultures and EHTs re-
sults in reductions in cardiac contractility through
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 6 , N O . 4 , 2 0 2 1 Bailey et al.
A P R I L 2 0 2 1 : 3 3 1 – 4 5 SARS-CoV-2 Infects Human Cardiomyocytes
343
sarcomere breakdown, disruption of metabolic gene
expression, and cardiomyocyte death. Collectively,
these findings show that SARS-CoV-2 can produc-
tively infect human cardiomyocytes and establish
an experimentally tractable platform for mecha-
nistic and therapeutic investigation of COVID-19
myocardial pathology.
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